AmeriPath Center For Advanced Diagnostics -CAD- Announces Addition Of ImmunoCyt to Test Menu; New Non-Invasive Test to Assist in Bladder Cancer Management.Business Editors/Health & Medical Writers RIVIERA BEACH, Fla.--(BUSINESS WIRE)--Feb. 20, 2001 AmeriPath, Inc. (Nasdaq:PATH), the largest physician and laboratory company focused on providing anatomic pathology and cancer diagnostics, genomics, and healthcare information services See Information Systems. , today announced that it will begin offering ImmunoCyt(TM), the first FDA-cleared cytopathology diagnostic test for the early detection of recurrent bladder cancer bladder cancer Malignant tumour of the bladder. The most significant risk factor associated with bladder cancer is smoking. Exposure to chemicals called arylamines, which are used in the leather, rubber, printing, and textiles industries, is another risk factor. (transitional cell carcinomas tran·si·tion·al cell carcinoma n. A malignant neoplasm derived from transitional epithelium and occurring primarily in the urinary bladder, ureters, or renal pelvises. transitional cell carcinoma Bladder cancer, see there ) at its Center for Advanced Diagnostics located in Orlando, Fla. ImmunoCyt(TM) is a highly sensitive, non-invasive test that allows urologists to detect antigens from tumors. Currently more than 300,000 people in the U.S. are being monitored for recurrence of bladder cancer and 55,000 new cases are detected annually. Bladder cancer is the sixth most common form of cancer in the United States. "As part of our expanding test menu, we are proud to offer ImmunoCyt(TM) as another diagnostic resource for our clinicians and patients. We believe that it will become a valuable addition to the traditional diagnostic algorithm in helping urologists manage recurrent bladder cancer," said Randy Judd, M.D., Director of Special Technologies at AmeriPath's Center for Advanced Diagnostics. "DAKO Corporation is pleased that AmeriPath and its Center for Advanced Diagnostics have added ImmunoCyt(TM) to their test menu. As one of the first commercial facilities to offer the test in the United States, they are leading the way in integrating this new tool into the current arsenal available to clinicians," said Douglas Sweet, DAKO's Vice President of Sales and Marketing. ImmunoCyt(TM) is licensed by DAKO Corporation from DiagnoCure, Inc. of Quebec City, Canada (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :CUR). AmeriPath's Center for Advanced Diagnostics is a comprehensive esoteric reference laboratory offering a full array of traditional and molecular diagnostics for hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. and solid tissue malignancies, including polymerase chain reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is (PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) ), in situ hybridization in situ hybridization A method for localizing a sequence of DNA, mRNA, or protein in a cell or tissue; the use of a DNA or RNA probe to detect a cDNA sequence in chromosome spreads or in interphase nuclei or an RNA sequence of cloned bacterial or cultured , cytogenetics cytogenetics /cy·to·ge·net·ics/ (-je-net´iks) the branch of genetics devoted to cellular constituents concerned in heredity, i.e. chromosomes. , flow cytometry flow cytometry (flōˑ sī·t  ˑ·m , specialized immunohistochemistry, and minimal residual disease residual disease Oncology Malignant cells or neoplasia that remains after any form–chemotherapy, surgery, RT–of 1º treatment detection. "AmeriPath, through our Center for Advanced Diagnostics, is committed to remaining on the cutting edge of pathology, molecular diagnostics, and genomics by continuing to research, implement and offer the latest diagnostic and prognostics tests and technologies available," added Dennis M. Smith, Jr., M.D., Senior Vice President and Medical Director for AmeriPath. AmeriPath, Inc. is the nation's largest company focused on providing anatomic pathology and cancer diagnostics, genomics, and related healthcare information services to physicians, hospitals, national clinical laboratories and managed care organizations. The Company's 425 physicians provide medical services through 42 outpatient pathology laboratories, 224 hospital inpatient laboratories, and 64 outpatient surgery centers in 21 states. The statements contained in this press release may include "forward-looking statements" which are based on management's current beliefs and expectations. Past performance is not necessarily indicative of future results. In addition, forward-looking statements - which are identified by words such as "may", "should", "believe", "expect", "anticipate", "estimate" and similar expressions - as well as any financial and operating estimates, forecasts and/or projections, are subject to a number of risks and uncertainties, many of which involve factors or circumstances which are beyond the Company's ability to control. These factors, risks and uncertainties could cause actual results to differ materially from historical results or those expected, estimated or anticipated. These include factors, risks and uncertainties relating to demand for pathology and related services, pricing, federal and state regulation (and compliance), reimbursement rates, government and third party payments, dependence upon pathologists, key personnel and contracts, competitive factors and technology. The forward looking statements included in this press release are made as of the date hereof, and the Company undertakes no obligation to update or revise any such statements, whether as result of new developments, new information or otherwise. Further information regarding risks, uncertainties and other factors that could affect the Company's financial or operating results, or which could cause actual results to differ materially from those expected or anticipated, are included in the Company's Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 1999 and subsequent filings with the SEC. Editor's Note: This release is also available at http://www.ameripath.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion